JP2018538246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538246A5 JP2018538246A5 JP2018521087A JP2018521087A JP2018538246A5 JP 2018538246 A5 JP2018538246 A5 JP 2018538246A5 JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018538246 A5 JP2018538246 A5 JP 2018538246A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- independently selected
- oxygen
- sulfur
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 90
- 229910052760 oxygen Inorganic materials 0.000 claims description 79
- 229910052717 sulfur Chemical group 0.000 claims description 79
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 72
- 239000001301 oxygen Chemical group 0.000 claims description 72
- 125000005842 heteroatom Chemical group 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 239000011593 sulfur Chemical group 0.000 claims description 68
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 64
- 229920006395 saturated elastomer Polymers 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 49
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 46
- 125000002950 monocyclic group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 150000002430 hydrocarbons Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- -1 2 -Cyclopropyl Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 241001646398 Pseudomonas chlororaphis Species 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 244000053095 fungal pathogen Species 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 230000008635 plant growth Effects 0.000 claims description 2
- 239000011814 protection agent Substances 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 2
- 102100038239 Protein Churchill Human genes 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 239000000575 pesticide Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 0 *C(CN(c([s]c(*)c1*)c1C(N1I*)=O)C1=O)O* Chemical compound *C(CN(c([s]c(*)c1*)c1C(N1I*)=O)C1=O)O* 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000162682 Heterogen Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- NRBDLLDVOJNIAK-LLVKDONJSA-N CC(C)C[C@@H](C=C)OC1CCOCC1 Chemical compound CC(C)C[C@@H](C=C)OC1CCOCC1 NRBDLLDVOJNIAK-LLVKDONJSA-N 0.000 description 1
- ZOWSJJBOQDKOHI-UHFFFAOYSA-N CC(OCC(F)(F)F)=O Chemical compound CC(OCC(F)(F)F)=O ZOWSJJBOQDKOHI-UHFFFAOYSA-N 0.000 description 1
- 208000008020 Cohen syndrome Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000012708 MOMO syndrome Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246318P | 2015-10-26 | 2015-10-26 | |
| US62/246,318 | 2015-10-26 | ||
| PCT/US2016/058867 WO2017075056A1 (en) | 2015-10-26 | 2016-10-26 | Acc inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538246A JP2018538246A (ja) | 2018-12-27 |
| JP2018538246A5 true JP2018538246A5 (enExample) | 2019-12-05 |
Family
ID=57233943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521087A Pending JP2018538246A (ja) | 2015-10-26 | 2016-10-26 | Ａｃｃ阻害剤およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10179793B2 (enExample) |
| EP (1) | EP3368540A1 (enExample) |
| JP (1) | JP2018538246A (enExample) |
| KR (1) | KR20180067603A (enExample) |
| CN (1) | CN108368125A (enExample) |
| AR (1) | AR106472A1 (enExample) |
| AU (1) | AU2016344392A1 (enExample) |
| BR (1) | BR112018008227A2 (enExample) |
| CA (1) | CA3003275A1 (enExample) |
| EA (1) | EA201890749A1 (enExample) |
| IL (1) | IL258636A (enExample) |
| MX (1) | MX2018005292A (enExample) |
| SG (1) | SG11201802989QA (enExample) |
| WO (1) | WO2017075056A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2665580T3 (es) | 2011-11-11 | 2018-04-26 | Gilead Apollo, Llc | Inhibidores de ACC y usos de los mismos |
| US10301292B2 (en) | 2014-11-26 | 2019-05-28 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| AU2016359626A1 (en) | 2015-11-25 | 2018-05-17 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine |
| KR20180082557A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 트리아졸 acc 억제제 및 그의 용도 |
| EA201890949A1 (ru) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
| EA201890913A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| BR112018067408A2 (pt) * | 2016-03-02 | 2018-12-26 | Gilead Apollo Llc | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas |
| EP3515919A1 (de) | 2016-09-23 | 2019-07-31 | Bayer Aktiengesellschaft | N3-cyclisch substituierte thienouracile und ihre verwendung |
| WO2018133858A1 (en) | 2017-01-22 | 2018-07-26 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| BR112019017915A2 (pt) * | 2017-03-03 | 2020-05-12 | Gilead Apollo, Llc | Processos para a preparação de compostos fungicidas |
| CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
| CN110709402B (zh) * | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
| US11186587B2 (en) | 2017-07-26 | 2021-11-30 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Compound as ACC inhibitor and use thereof |
| CA3094988A1 (en) | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| JP7275444B2 (ja) * | 2018-06-05 | 2023-05-18 | メッドシャイン ディスカバリー インコーポレイテッド | チエノ［２，３－ｃ］ピリダジン－４（１Ｈ）－オン系誘導体及びその使用 |
| US20220015361A1 (en) * | 2018-11-02 | 2022-01-20 | Dow Agrosciences Llc | Compositions comprising halauxifen and other herbicides and methods thereof |
| WO2020103851A1 (zh) * | 2018-11-20 | 2020-05-28 | 中国医药研究开发中心有限公司 | 螺环类化合物及其医药用途 |
| CN111484504B (zh) * | 2019-01-25 | 2024-05-10 | 南京圣和药业股份有限公司 | Acc抑制剂的光学异构体及其应用 |
| US20220152164A1 (en) * | 2019-03-22 | 2022-05-19 | Kallyope, Inc. | Gpcr combination therapies |
| WO2021000242A1 (zh) | 2019-07-02 | 2021-01-07 | 广东东阳光药业有限公司 | 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN110746439B (zh) * | 2019-10-18 | 2020-10-30 | 南京瑞捷医药科技有限公司 | 一种噻吩并嘧啶二酮化合物的制备方法 |
| WO2021112213A1 (ja) * | 2019-12-05 | 2021-06-10 | 日本曹達株式会社 | ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤 |
| US11673899B2 (en) | 2019-12-05 | 2023-06-13 | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof |
| WO2021110135A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 作为acc1和acc2抑制剂的晶型及其制备方法和应用 |
| KR20230004575A (ko) * | 2020-04-08 | 2023-01-06 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN113968871A (zh) * | 2020-07-25 | 2022-01-25 | 南京圣和药业股份有限公司 | 苯基取代类acc抑制剂的晶型 |
| WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
| TW202241908A (zh) | 2020-12-24 | 2022-11-01 | 日商模數探索股份有限公司 | 四氫噻吩并嘧啶磺醯胺化合物 |
| WO2022268520A1 (de) * | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
| CN115677551A (zh) * | 2021-12-28 | 2023-02-03 | 武汉市振邦生物科技有限公司 | 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺 |
| KR20250046274A (ko) | 2022-08-05 | 2025-04-02 | 길리애드 사이언시즈, 인코포레이티드 | SARS-CoV2 주요 프로테아제 억제제 |
| CN115433756B (zh) * | 2022-08-30 | 2024-04-09 | 山东新华制药股份有限公司 | 一种泼尼松龙的制备方法 |
| US20250276979A1 (en) * | 2024-02-07 | 2025-09-04 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670560A (en) | 1986-04-28 | 1987-06-02 | Ortho Pharmaceutical Corporation | Thienopyrimidine-2,4-dione derivatives and intermediates thereof |
| US4835157A (en) * | 1988-03-15 | 1989-05-30 | Ortho Pharmaceutical Corporation | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents |
| JPH02225485A (ja) | 1989-02-27 | 1990-09-07 | Taiho Yakuhin Kogyo Kk | チエノピリミジン―３―酢酸誘導体 |
| JP3035745B2 (ja) * | 1990-02-22 | 2000-04-24 | 武田薬品工業株式会社 | 縮合チオフェン誘導体 |
| TW276256B (enExample) | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
| JP3811196B2 (ja) | 1993-08-26 | 2006-08-16 | 武田薬品工業株式会社 | エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法 |
| WO2000061583A1 (en) | 1995-06-07 | 2000-10-19 | Cell Therapeutics, Inc. | Xanthine derivatives and analogs as cell signaling inhibitors |
| ATE227726T1 (de) | 1995-08-17 | 2002-11-15 | Takeda Chemical Industries Ltd | Thienopyrimidinderivate als endothelin antagonisten |
| JPH09110873A (ja) | 1995-08-17 | 1997-04-28 | Takeda Chem Ind Ltd | チエノピリミジン誘導体、その製造法および用途 |
| WO1997040846A1 (en) | 1996-04-30 | 1997-11-06 | Takeda Chemical Industries, Ltd. | COMBINED USE OF GnRH AGONIST AND ANTAGONIST |
| JP2007302703A (ja) | 1996-04-30 | 2007-11-22 | Takeda Chem Ind Ltd | 医薬組成物 |
| SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| US6984644B2 (en) | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
| DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
| US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
| WO2002064598A1 (en) | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| JP5072166B2 (ja) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | チエノピリミジン化合物、その製造法および用途 |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| ATE425668T1 (de) | 2003-01-06 | 2009-04-15 | Yissum Res Dev Co | Pflanzliche acetyl-coa carboxylase-hemmende herbizide als pestizide |
| PT1591446E (pt) | 2003-01-29 | 2013-06-12 | Takeda Pharmaceutical | Compostos de tienopirimidina e sua utilização |
| US7947691B2 (en) | 2004-07-21 | 2011-05-24 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| JP2009528389A (ja) | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシン受容体拮抗剤 |
| WO2008143262A1 (ja) * | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| MX2012007548A (es) | 2009-12-29 | 2012-07-23 | Poxel | Activadores de tienen [2,3-b] piridindiona de proteina quinasa activada con amp y usos terapeuticos de los mismos. |
| EP2569450A4 (en) * | 2010-05-14 | 2013-12-25 | Univ Rochester | COMPOSITIONS AND METHODS FOR TARGETING A3G: RNA COMPLEXES |
| ES2665580T3 (es) * | 2011-11-11 | 2018-04-26 | Gilead Apollo, Llc | Inhibidores de ACC y usos de los mismos |
| CN105358155A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| CA2911932A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| CA2911818A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
| MX2015015417A (es) * | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| TWI652012B (zh) | 2013-05-20 | 2019-03-01 | 杜邦股份有限公司 | 殺真菌吡唑的固態形式 |
| WO2015007453A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| EA201890913A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| AU2016359626A1 (en) | 2015-11-25 | 2018-05-17 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine |
| EA201890949A1 (ru) | 2015-11-25 | 2018-12-28 | Джилид Аполло, Ллс | СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ |
| KR20180082557A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 트리아졸 acc 억제제 및 그의 용도 |
| BR112018067408A2 (pt) | 2016-03-02 | 2018-12-26 | Gilead Apollo Llc | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas |
-
2016
- 2016-10-25 AR ARP160103255A patent/AR106472A1/es unknown
- 2016-10-26 CA CA3003275A patent/CA3003275A1/en not_active Abandoned
- 2016-10-26 US US15/334,955 patent/US10179793B2/en not_active Expired - Fee Related
- 2016-10-26 SG SG11201802989QA patent/SG11201802989QA/en unknown
- 2016-10-26 BR BR112018008227A patent/BR112018008227A2/pt not_active Application Discontinuation
- 2016-10-26 MX MX2018005292A patent/MX2018005292A/es unknown
- 2016-10-26 KR KR1020187013132A patent/KR20180067603A/ko not_active Withdrawn
- 2016-10-26 EP EP16791253.4A patent/EP3368540A1/en not_active Withdrawn
- 2016-10-26 JP JP2018521087A patent/JP2018538246A/ja active Pending
- 2016-10-26 WO PCT/US2016/058867 patent/WO2017075056A1/en not_active Ceased
- 2016-10-26 EA EA201890749A patent/EA201890749A1/ru unknown
- 2016-10-26 CN CN201680072737.1A patent/CN108368125A/zh active Pending
- 2016-10-26 AU AU2016344392A patent/AU2016344392A1/en not_active Abandoned
-
2018
- 2018-04-11 IL IL258636A patent/IL258636A/en unknown
- 2018-11-27 US US16/201,571 patent/US20190330224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520063A5 (enExample) | ||
| JP2018536661A5 (enExample) | ||
| JP2019502660A5 (enExample) | ||
| JP2018536660A5 (enExample) | ||
| TWI297335B (en) | Taxol enhancer compounds | |
| PE20241341A1 (es) | Compuestos terapeuticos para la infeccion por el virus vih | |
| JP2016526024A5 (enExample) | ||
| JP2016520064A5 (enExample) | ||
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
| KR950700265A (ko) | 고지혈증 치료에 유용한 벤조티아제핀 화합물(hypolipidaemic ben zothiazepine compounds) | |
| RU2018106453A (ru) | Соединения | |
| EA202191967A1 (ru) | Замещенные полициклические карбоновые кислоты, их аналоги и способы их применения | |
| MX2024010631A (es) | Derivados ciclicos de panteteina y usos de los mismos | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| JP2017523225A5 (enExample) | ||
| WO2012107706A8 (en) | Phenothiazine diaminium salts and their use | |
| RU2010143857A (ru) | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибриторов parp и ингибиторов полимеризации тубулина | |
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| AR129378A1 (es) | Compuestos de indolinilo antivirales y usos de estos | |
| AR044856A1 (es) | Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. | |
| PE20161432A1 (es) | Compuestos y composiciones para inducir condrogenesis | |
| JP2011516511A5 (enExample) | ||
| JP2019501879A5 (enExample) |